Welcome to our dedicated page for Deciphera Pharmaceuticals news (Ticker: DCPH), a resource for investors and traders seeking the latest updates and insights on Deciphera Pharmaceuticals stock.
Deciphera Pharmaceuticals, Inc. (symbol: DCPH) is a biotechnology company founded in 2003 with a deep scientific understanding of kinase inhibitors. Based in Boston, with research capabilities near the University of Kansas, Deciphera specializes in developing advanced kinase-inhibiting drugs for cancer and immunological diseases. The company has identified small molecule leads for over 50 kinase targets and has built a robust pipeline of drug candidates, including three clinical-stage and two research-stage programs.
The company's lead drug candidate, DCC-2618, is designed to inhibit mutant or amplified KIT and Pdgfra kinases, which drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, Deciphera is developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib, which are focused on treating different types of cancers.
Geographically, Deciphera's operations are concentrated in the United States. The company has recently achieved significant milestones, including the successful completion of a tender offer by Ono Pharmaceutical Co., Ltd. to acquire all outstanding shares of Deciphera for approximately $2.4 billion. Following this acquisition, Deciphera became a wholly owned subsidiary of Ono, who will leverage its research and development capabilities in oncology and its sales power in Europe and the United States to expand its global presence.
The merger with Ono Pharmaceutical marks a new phase for Deciphera, where the combined expertise and resources are expected to accelerate the growth of their pipeline and contribute significantly to the global fight against cancer and other diseases.
Deciphera Pharmaceuticals (NASDAQ: DCPH) plans to initiate the pivotal Phase 3 INSIGHT study of QINLOCK versus sunitinib for second-line GIST patients with specific KIT mutations in late 2023. The company also expects to complete enrollment in the Phase 3 MOTION study of vimseltinib in the first half of 2023, announcing results later in the year. Preliminary unaudited revenue for Q4 2022 is estimated at $36 million, with a total of $134 million for the year. As of December 31, 2022, the company reported approximately $339 million in cash and equivalents, positioning it to fund operations through 2025.
Deciphera Pharmaceuticals (DCPH) announced positive results from an exploratory analysis of QINLOCK in the INTRIGUE Phase 3 study, notably for patients with specific KIT mutations. Key findings include a median progression-free survival (PFS) of 14.2 months for QINLOCK, compared to 1.5 months for sunitinib, with a hazard ratio of 0.22. The objective response rate was 44.4% for QINLOCK versus 0% for sunitinib. The company plans to initiate a pivotal Phase 3 clinical study, known as INSIGHT, in the second half of 2023.
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) has announced that CEO Steve Hoerter will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 9:45 AM PT. A live webcast of the presentation will be accessible via the company’s website, with a replay available for 30 days afterward. Deciphera focuses on developing innovative cancer treatments, utilizing its proprietary switch-control kinase inhibitor platform. The company's QINLOCK® is already approved in several markets, including the United States and Europe.
Deciphera Pharmaceuticals (NASDAQ: DCPH) will have its CEO, Steve Hoerter, participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on December 6, 2022, at 10:40 AM ET. A live webcast can be accessed on the Company’s website under the 'Events and Presentations' section, with a replay available for 90 days post-event. Deciphera focuses on innovative cancer treatments and is advancing its proprietary switch-control kinase inhibitor platform, including the approved product QINLOCK® for fourth-line GIST treatment.
Deciphera Pharmaceuticals will participate in multiple investor conferences in November 2022. Key dates include:
- Stifel Healthcare Conference on November 15 at 10:55 AM ET in New York, NY
- Jefferies London Healthcare Conference on November 17 at 8:30 AM ET in London
- Piper Sandler 34th Annual Healthcare Conference on November 29 at 4:00 PM ET in New York, NY
Live webcasts will be accessible via the company’s investor website, with replays available for 90 days.
Deciphera is focused on developing innovative cancer therapies, including QINLOCK®, approved in multiple countries.
Deciphera Pharmaceuticals (DCPH) reported a third quarter 2022 total revenue of $36.0 million, a significant increase from $23.2 million in Q3 2021. The net product revenue for QINLOCK® rose 49% to $32.3 million. The company presented promising results for vimseltinib and DCC-3116 at the ESMO Congress 2022, showcasing their potential in treating cancer. DCPH reported a net loss of $43.0 million or $0.55 per share, an improvement from last year's $79.8 million loss. The company maintains a strong cash position of $371.6 million to fund operations into 2025.
Deciphera Pharmaceuticals (NASDAQ: DCPH) announced it will report its third quarter 2022 financial results on November 3, 2022, at 8:00 AM ET. A live conference call will follow, providing insights into the financial results and corporate updates. The earnings announcement is anticipated to shed light on Deciphera's performance, especially regarding its innovative cancer therapies using their proprietary switch-control kinase inhibitor platform. QINLOCK®, their treatment for fourth-line GIST, is already approved in multiple regions, including the US and EU.
Deciphera Pharmaceuticals (NASDAQ: DCPH) announced updated results for vimseltinib, a treatment for patients with tenosynovial giant cell tumor (TGCT), showing an objective response rate of 69% in Phase 1 and 53% to 46% in Phase 2 cohorts. The clinical benefit rate was 100%. Preliminary patient-reported outcomes indicated significant improvements in pain and stiffness. The ongoing Phase 3 MOTION study supports further investigation of vimseltinib, with a virtual investor event scheduled for September 11.
Deciphera Pharmaceuticals announced promising data from the Phase 1 study of its drug DCC-3116, a selective ULK1/2 inhibitor, targeting advanced cancers with RAS or RAF mutations. The drug was well-tolerated, with no serious adverse events, and demonstrated significant pharmacokinetic effects linked to anti-tumor efficacy. Dose escalation cohorts with MEK and KRASG12C inhibitors are expected to begin in Q4 2022. Initial results showed that 29% of patients achieved disease control at week 16.
Deciphera Pharmaceuticals (NASDAQ: DCPH) will host a virtual investor event on September 11, 2022, from 7:30 AM to 9:30 AM ET. The event will showcase clinical data from its DCC-3116 and vimseltinib programs, coinciding with the ESMO Congress 2022. Key opinion leaders Anthony W. Tolcher, M.D., and Jean-Yves Blay, M.D., Ph.D., will present findings. Attendees can register here. The presentations include DCC-3116 monotherapy results and vimseltinib's efficacy in treating tenosynovial giant cell tumors.
FAQ
What is the current stock price of Deciphera Pharmaceuticals (DCPH)?
What is the market cap of Deciphera Pharmaceuticals (DCPH)?
What does Deciphera Pharmaceuticals, Inc. specialize in?
Where is Deciphera Pharmaceuticals based?
What are the key drug candidates in Deciphera's pipeline?
What is DCC-2618 designed to treat?
Who acquired Deciphera Pharmaceuticals and for how much?
What will be the impact of the acquisition by Ono Pharmaceutical on Deciphera Pharmaceuticals?
What is the significance of Deciphera becoming a wholly owned subsidiary of Ono?
What are the research capabilities of Deciphera Pharmaceuticals?
Are Deciphera's operations limited to the United States?
What recent achievements has Deciphera Pharmaceuticals accomplished?
